throbber
United States Patent [19J
`Hughes
`
`[54) RAPAMYCIN ALKOXYESTERS
`
`[75]
`
`Inventor: Philip F. Hughes, Hopewell, N.J.
`
`[73) Assignee: American Home Products
`Corporation, New York, N.Y.
`
`[21) Appl. No.: 839,653
`
`[22] Filed:
`
`Feb. 20, 1992
`
`Related U.S. Application Data
`[63] Continuation of Ser. No. 598.270, Oct. 16, 1990, aban(cid:173)
`doned.
`
`Int. Cl.5 .................... C07D 269/00; A61K 31/33
`[51]
`[52] U.S. Cl. .................................................... 540/455
`[58] Field of Search ......................... 540/455; 514/183
`
`[56]
`
`References Cited
`U.S. PATENT DOCUMENTS
`3,929,992 12/1975 Sehgal et al. ....................... 424/122
`3,993.749 11/1976 Sehgal et al. ....................... 424/122
`4,316.885 2/1982 Rakhit et al. ....................... 424/122
`4,401,653 4/1983 Maruyama et al. ................. 424/122
`4,650,803 3/1987 Stella et al. ........................... 546/90
`4,885.171 12/1989 Sehgal et al. ....................... 424/122
`4,929,611 5/1990 Okuhava ............................. 514/183
`
`OTHER PUBLICATIONS
`Can. J. Physiol. Pharmacol. 55, 48 (1977).
`FASEB 3, 3411 (1989).
`FASEB 3, 5256 (1989).
`Lancet, 1183, (1978).
`J. Am. Chem. Soc. 103, 3215 (1981).
`J. Am. Chem. Soc. 104, 6787 (1982).
`J. Antibiot. 28, 721-726 (1975).
`J. Antibiot. 28, 727-732 (1975).
`J. Antibiot. 31, 539-545 (1978).
`
`Primary Examiner-C. Warren Ivy
`Assistant Examiner-Celia Chang
`Attorney, Agent, or Firm-Arnold S. Milowsky
`
`I lllll llllllll Ill lllll lllll lllll llllH~ll 111111111111111111111111111111111
`US005233036A
`.5,233,036
`[11) Patent Number:
`[45) Date of Patent:
`Aug. 3, 1993
`
`ABSTRACT
`[57]
`A compound of the structure
`
`wherein RI is
`
`R2is hydrogen, alkyl of 1-6 carbon atoms, cy.cloalkyl of
`3-8 carbon atoms which is optionally unsaturated,
`aralkyl of 7-10 carbon atoms. or phenyl which is
`optionally mono-, di-, or tri-substituted with a substit(cid:173)
`uent selected from alkyl of 1-6 carbon atoms, alkoxy
`of 1-6 carbon atoms, hydroxy, cyano, halo, nitro,
`carbalkoxy of 2-7 carbon atoms, trifluoromethyl,
`amino, or a carboxylic acid;
`or a pharmaceutically acceptable salt thereof when R2is
`hydrogen, which are useful in the treatment of trans(cid:173)
`plantation rejection, host vs. graft disease, autoimmune
`diseases, diseases of inflammation, or fungal infections.
`
`4 Claims, No Drawings
`
`Breckenridge Exhibit 1009
`Breckenridge v. Novartis AG
`
`

`
`1
`
`5,233,036
`
`RAPAMYCIN ALKOXYESTERS
`
`This is a continuation of application Ser. No. 5
`07/598,270 filed Oct. 16, 1990 now abandoned.
`
`BACKGROUND OF THE INVENTION
`
`2
`
`OR 1
`
`0
`
`0
`
`N
`
`I
`0
`
`~O
`
`OMe
`
`MeO __ _
`
`wherein RI is
`
`R2is hydrogen, alkyl of 1-6 carbon atoms, cycloalkyl of
`3-8 .carbon atoms which is optionally unsaturated,
`aralkyl of 7-10 carbon atoms, or phenyl which is
`optionally mono-, di-, or tri-substituted with a substit(cid:173)
`uent selected from alkyl of 1-6 carbon atoms, alkoxy
`of 1-6 carbon atoms, hydroxy, cyano, halo, nitro,
`carbalkoxy of 2-7 carbon atoms, trifluoromethyl,

`amino, or a carboxylic acid;
`or a pharmaceutically acceptable salt thereof when R2is
`hydrogen.
`Of the compounds, preferred members are those in
`which R2 is alkyl of 1-6 carbon atoms.
`The pharmaceutically acceptable salts may be formed
`from inorganic cations such as sodium, potassium, cal(cid:173)
`cium, magnesium and the like or may be in the form of
`a quaternary ammonium salt.
`The compounds of this invention can be prepared by
`reacting rapamycin with the appropriately substituted
`ester of diazoacetic acid in the presence of a divalent
`cation salt, such as rhodium (II) diacetate dimer or
`copper (II) triflate, as shown below.
`
`This method of preparing alkoxyesters has been de(cid:173)
`scribed by B. Ganem et al., J. Am. Chem. Soc. 104, 6787
`(1982). The starting materials utilized are either com(cid:173)
`mercially available or can be prepared by methods dis(cid:173)
`closed in the literature.
`The compounds of this invention, rapamycin-42-
`ethers, provide stability against hydrolysis of the 42-side
`chain by virtue of the ether moiety connecting the side
`chain to rapamycin at the 42-position.
`Immunosuppressive activity was evaluated in an in
`vitro standard pharmacological test procedure to mea(cid:173)
`sure lymphocyte proliferation (LAF) and in two in vivo
`standard pharmacological test procedures. The first in
`vivo procedure was a popliteal lymph node (PLN) test
`procedure which measured the effect of compounds of
`this invention on a mixed lymphocyte reaction and the
`
`15
`
`25
`
`35
`
`45
`
`This invention relates to novel ethers of rapamycin JO
`and a method for using them in the treatment of trans(cid:173)
`plantation rejection, host vs. graft disease, autoimmune
`diseases, diseases of inflammation or fungal infections.
`Rapamycin is a macrocyclic triene antibiotic pro-
`duced by Streptomyces hygroscopicus, which was found
`to have antifungal activity, particularly against Candida
`a/bicans, both in vitro and in vivo [C. Vezina et al., J. 20
`Antibiot. 28, 721 (1975); S. N. Seghal et al., J. Antibiot.
`28, 727 (1975); H. A. Baker et al., J. Antibiot. 31, 539
`(1978); U.S. Pat. No. 3,929,992; and U.S Pat. No.
`3,993,749].
`Rapamycin alone (U.S. Pat. No. 4,885.171) or in com(cid:173)
`bination with picibanil (U.S. Pat. No. 4,401,653) has
`been shown to have antitumor activity. R. Martel et al. 30
`[Can. J. Physiol. Pharmacol. 55. 48 (1977)] disclosed
`that rapamycin is effective in the experimental allergic
`encephalomyelitis model, a model for multiple sclerosis;
`in the adjuvant arthritis model, a model for rheumatoid
`arthritis; and effectively inhibited the formation of lgE(cid:173)
`like antibodies.
`The immunosuppressive effects of rapamycin have 40
`been disclosed in F ASEB 3, 3411 ( 1989). Cyclosporin A
`and FK-506, other macrocyclic ·molecules, also have
`been shown to be effective as immunosuppressive
`agents, therefore useful in preventing transplant rejec-
`tion [F ASEB 3, 3411 ( 1989); F ASEB 3, 5256 ( 1989); and
`R. Y. Caine et al., Lancet 1183 (1978)].
`Mono- and diacylated derivatives of rapamycin (es- so
`terified at the 28 and 43 positions) have been shown to
`be useful as antifungal agents (U.S. Pat. No. 4,316,885)
`and used to make water soluble prodrugs of rapamycin
`.
`(U.S. Pat. No. 4,650,803). Recently, t e num nng
`be
`h
`convention for rapamycin has been changed; therefore
`according to Chemical Abstracts nomenclature, the
`esters described above would be at the 31- and 42- posi- 60
`tions.
`
`55
`
`DESCRIPTION OF THE INVENTION
`
`This invention provides derivatives of rapamycin 65
`which are useful as immunosuppressive. anti-inflamma(cid:173)
`tory, or antifungal agents having the structure
`
`

`
`5,233,036
`
`4
`The following table summarizes the results of repre(cid:173)
`sentative compounds of this invention in these three
`standard test procedures.
`TABLE 1
`Skin Graft
`LAF*
`PLN*
`(days+ SD)
`(ratio)
`(ratio)
`Compound
`7.5 ± 1.2
`0.46
`0.74**
`Example I
`0.27
`Example 2
`+
`+
`12.0 ± 1.7
`1.0
`Rapamycin
`1.0
`--...:....~------------------
`•Calculation of ratio!t wa~ described supra.
`.. A result of -0.14 also was obtained for Example 1.
`+Not evaluated
`
`3
`second in vivo procedure evaluated the survival time of
`a pinch skin graft.
`The comitogen-induced thymocyte proliferation pro(cid:173)
`cedure (LAF) was used as an in vitro measure of the
`immunosuppressive effects of representative com- 5
`pounds. Briefly, cells from the thymus of normal
`BALB/c mice are cultured for 72 hours with PHA and
`IL-1 and pulsed with tritiated thymidine during the last
`six hours. Cells are cultured with and without various
`concentrations of rapamycin, cyclosporin A, or test
`compound. Cells are harvested and incorporated; radio(cid:173)
`activity is determined. Inhibition of lymphoprolifera(cid:173)
`tion is assessed in percent change in counts per minute
`from non-drug treated controls. The results are ex- 15
`pressed by the following ratio, or as th~ percent inhibi(cid:173)
`tion of lymphoproliferation of I µM.
`
`10
`
`3H-control thymus cells - H'-rapamycin-treated thvmus celb
`'H-control thymus celb - H'-test compound-treated cells
`
`25
`
`The results of the LAF standard pharmacological
`test procedure demonstrates that the compound of Ex(cid:173)
`ample 2 suppressed T-cell proliferation, and is therefore
`useful as an immunosuppressive agent. Based on the
`results of the in vitro and in vivo standard pharmaco(cid:173)
`logical test procedures, it was unclear whether the com-
`20 pound of Example 1 had immunosuppressive activity. A
`ratio of0.46 in the LAF and 0. 74 in the PLN test proce(cid:173)
`dures indicates that the compound of Example 1 sup(cid:173)
`pressed T-cell proliferation; however, the -0.14 ratio
`that was also obtained in the PLN test procedure could
`be indicative of immunostimulation.
`Antifungal activity of the compounds of this inven(cid:173)
`tion was measured against 5 strains of Candida albicans
`using a plate test procedure for measurement of inhibi(cid:173)
`tion. The following represents the typical procedure
`used. Compound to be tested was placed on sterile dried
`l" plate disks, and allowed to dry. Agar plates were
`seeded with fungi and allowed to solidify. The impreg(cid:173)
`nated disks were placed on the seeded Agar surface and
`incubated for the time required for the particular cul(cid:173)
`ture. Results are expressed in MIC (µg/ml) to inhibit
`growth. The results of this test procedure showed that
`the compounds of this invention have antifungal activ(cid:173)
`ity.
`
`A mixed lymphocyte reaction (MLR) occurs when
`lymphoid cells from genetically distinct animals are
`combined in tissue culture. Each stimulates the other to
`undergo blast transformation which results in increased
`DNA synthesis that can be quantified by the incorpora(cid:173)
`tion oftritiated thymidine. Since stimulating a MLR is a
`function of disparity at Major Histocompatibility anti(cid:173)
`gens, as in vivo popliteal lymph node (PLN) test proce- 30
`dure closely correlates to host vs. graft disease. Briefly,
`irradiated spleen cells from BALB/c donors are in(cid:173)
`jected into the right hind foot pad of recipient C3H
`mice. The drug is given daily, p.o. from Day 0 to Day
`4. On Day 3 and Day 4, tritiated thymidine is given i.p., 35
`b.i.d .. On Day 5, the hind popliteal lymph nodes are
`removed and dissolved, and radioactivity counted. The
`corresponding left PLN serves as the control for the
`PLN from the injected hind foot. Percent suppression is
`calculated using the non-drug treated animals as allo- 40
`genie control. Rapamycin at a dose of 6 mg/kg, p.o.
`gave 86% suppression, whereas cyclosporin A at the
`same dose gave 43% suppression. Results are expressed
`by the following ratio:
`
`TABLE 2*
`Strain of Candida a/bicans
`ATCC
`ATCC
`ATCC
`!0231
`38246
`38247
`
`0.5
`0.05
`0.003
`
`0.1
`0.2
`0.025
`
`0.2
`0.05
`0.003
`
`ATCC
`38248
`
`0.1
`0.1.
`0.006
`
`3669
`
`0.05
`0.2
`0,025
`
`Compound
`Example I
`Example 2
`Rapamycin
`
`•expressed a. MIC (µg/mlJ
`
`45
`
`'H-PLN cells control C3H mouse -
`'H-PLN cells rapamycin-treated C3H mouse
`JH-PLN celb control C3H mouse -
`3H-PLN cells test compound-treated C3H mouse
`
`The second in vivo test procedure is designed to
`determine the survival time of pinch skin graft from
`male DBA/2 donors transplanted to male BALB/c
`recipients. The method is adapt~d from Billingham R. 55
`E. and Medawar P. B., J. Exp. Btol. 28:385-402, (1951).
`Briefly, a pinch skin graft from the donor is grafted on
`the dorsum of the recipient as a homograft, and an
`autograft is used as control in the same region. The
`recipients are treated with either varying concentra- 60
`tions of cyclosporin A as test control or the test com(cid:173)
`pound, intraperitoneally. Untreated recipients serve as
`rejection control. The graft is monitored daily and ob(cid:173)
`servations are recorded until the graft becomes dry and
`forms a blackened scab. This is considered as the rejec- 65
`tion day. The mean graft survival time (number of
`days±S.D.) of the drug treatment group is compared
`with the control group.
`
`Based on the results of these standard pharmacologi(cid:173)
`cal test procedures, the compounds are useful in the
`50 treatment of transplantation rejection such as, heart,
`kidney, liver, bone marrow, and skin transplants; auto(cid:173)
`immune diseases such as, lupus, rheumatoid arthritis,
`diabetes mellitus, myasthenia gravis, and multiple scle-
`rosis; and diseases of inflammation such as, psoriasis,
`dermatitis, eczema, seborrhea, inflammatory bowel
`disease; or fungal infections.
`The compounds may be administered neat or with a
`pharmaceutical earner to a mammal in need thereof.
`The pharmaceutical carrier may be solid or liquid.
`A solid carrier can include one or more substances
`which may also act as flavoring agents, lubricants, solu(cid:173)
`bilizers, suspending agents, fillers, glidants, compression
`aids, binders or tablet-disintegrating agents; it can also
`be an encapsulating material. In powders, the carrier is
`a finely divided solid which is in admixture with the
`finely divided active ingredient. In tablets, the active
`ingredients is miAed with a carrier having the necessary
`compression properties in suitable proportions and
`
`

`
`5,233,036
`
`6
`chloride for 3 d to yield a white powder which was
`filtered to give 42-deoxy-42-(2-ethoxy-2-oxoethoxy)(cid:173)
`rapamycin (496 mg, 23%). The product was isolated as
`the hemihydrate. IR (KBr) 1680, 1730, 2920, 3430
`cm-1; IH-NMR (CDCL3)01.28 (3H, t, J=7.14 Hz),
`1.65 (3H, s), 1.74 (3H, s) 3.14 (3H, s), 3.34 (3H, s), 3. 41
`(3H, s), 4.20 (2H, q, J=7.14 Hz), 4.30 (2H, dd); Mass
`Spect (neg. ion F AB) m/z 999 (94% ), 590 (15% ), 407
`(16%), 379 (4%), 253 (6%), 167 (100%).
`Analysis Calcd for Css Hss N 01s e0.5 H20:C, 65.45;
`H, 8.59; N, 1.39 Found: C, 65.29; H, 8.64; N, 1.60.
`The following representative compounds can be pre(cid:173)
`pared from rapamycin and the appropriately substituted
`ester of diazoacetic acid by employing the method used
`to prepare the title compound in Example 1. 42-Deoxy-
`42-(2-phenoxy-2-oxoethoxy)rapamycin 42-Deoxy-42-
`[2-( 4-chlorophenoxy )-2-oxoethoxy ]rapamycin
`42-
`Deoxy-42-(2-phenylmethoxy )-2-oxoethoxy )rapamycin
`42-Deoxy-42-(2-cyclobotoxy)-2-oxoethoxy)rapamycin
`42-Deoxy-42-[2-(cyclohex-2~nyloxy)-2-oxoethoxy]-
`rapamycin
`
`5
`compacted in the shape and size desired. The powders
`and tablets preferably contain up to 99% of the active
`ingredient. Suitable solid carriers include, for example,
`calcium phosphate, magnesium stearate, talc, sugars,
`lactose, dextrin, starch, gelatin, cellulose, methyl cellu- 5
`lose, sodium carboxymethyl cellulose, polyvinylpyr(cid:173)
`rolidine, low melting waxes and ion exchange resins.
`Liquid carriers are used in preparing solutions, sus(cid:173)
`pensions, emulsions, syrups, elixirs and pressurized
`compositions. The active ingredient can be dissolved or JO
`suspended in a pharmaceutically acceptable liquid car~
`rier such as water, an organic solvent, a mixture of both
`or pharmaceutically acceptable oils or fats. The liquid
`carrier can contain other suitable pharmaceutical addi(cid:173)
`tives such as solubilizers, emulsifiers, buffers, preserva- J5
`tives, sweeteners, flavoring agents, suspending agents,
`thickening agents, colors, viscosity regulators, stabiliz(cid:173)
`ers or osmo-regulators. Suitable examples of liquid car(cid:173)
`riers for oral and parenteral administration include
`water (partially containing additives as above, e.g. eel- 20
`lulose derivatives, preferably sodium carboxymethyl
`cellulose solution), alcohols (including monohydric
`alcohols and polyhydric alcohols, e.g. glycols) and their
`derivatives, and oils (e.g. fractionated coconut oil and
`arachis oil). For parenteral administration, the carrier 25
`can also be an oily ester such as ethyl oleate and isopro-
`pyl myristate. Sterile liquid carriers are useful in sterile
`liquid form compositions for parenteral administration.
`To solution of rapamycin (2.0 g, 2.187 mmol) and
`rhodium (II) diacetate (20 mg, 0.04 mmol) in methylen
`The liquid carrier for pressurized compositions can be
`halogenated hydrocarbon or other pharmaceutically 30 chloride (50 mL) was added with t-butyl diazoacetate
`(750 mg, 690 µL, 6.56 mmol) in methylene chloride (20
`acceptable propellent.
`Liquid pharmaceutical compositions which are sterile
`mL) over 1.5 hand the reaction mixture was allowed to
`solutions or suspensions can be utilized by, for example,
`stir overnight. The mixture was concentrated and puri-
`intramuscular, intraperitoneal or subcutaneous injec-
`fied by chromatography (silica gel, ethyl acetate-hex-
`tion. Sterile solutions can also be administered intrave- 35 ane, 4:6) to give the product as a glass. The product was
`dissolved with methylene chloride and concentrated to
`nously. The compound can also be administered orally
`give the product as a while solid (588 mg, 26%). The
`either in liquid or solid composition form.
`Preferably, the pharmaceutical composition is in unit
`product was then dried in vacua at 68° C. overnight and
`dosage form, e.g. as tablets or capsules. In such form,
`isolated as the hemihydrate. IR (KBr) 1650 1725 1750
`the com_position i~ ~uh-divided i.n u?it dos_e containin~ 40 2940, 3440 cm-1; IH-NMR (CDCL3)ol.47 '(9H, ~), l.6S
`appropnate quantities of the active mg:c:dient; the umt
`(3H, s), 1. 74 (3H, s), 3.14 (3H, s) 3.34 (3H, s) 3.34 (3H, s),
`dosage forms can be pac~aged compositions, for exa~-
`4.20 (2H, dd); Mass spect (neg. ion F AB) m/z 1027
`pie, packeted powdc:r~, v1~Js, _ampoules, !?refilled syrm-
`(32%), 590 (13%), 435 (9%), l67 (100%).
`.
`ges or sachets contammg hqu1ds. The umt dosage form
`A 1 · C 1 d ,. C H N 0
`0 5 H O·C
`s1 89
`66 00. ,
`
`,.
`bl

`If

`b
`na ys1s
`a c 1or
`159 .
`2 . ,
`
`1
`1
`can be, ior e~amp e, a capsu e or ta et itse , or~·- can . e 45 H 8. 74· N 1.35 Found: C 65.83· H 8.60· N 1.29.
`'wh ' . '
`. d .
`'
`'
`'
`'
`'
`the appropnate number of any such compos1t1ons m
`1
`· h
`at 1s c a1me 1s:
`package form. The dosage to be used m t e treatment
`must be subjectively determined by the attending physi-
`1. A compound of the structure
`cian.
`In addition, the compounds of this invention may be 50
`employed as a solution, cream, or lotion by formulation
`with pharmaceutically acceptable vehicles containing
`0.1-0.5 percent, preferably 2%, of active compound
`which may be administered to a fungally affected area.
`The following examples illustrate the preparation of 55
`representative compounds of this invention.
`
`EXAMPLE 2
`42-Deoxy-42-[2-(l, l-dimethylethoxy)-2-oxoethoxy]-
`rapamycin
`
`EXAMPLEi
`
`42-Deoxy-42-(2~thoxy-2-oxoethoxy)rapamycin
`A solution of rapamycin (2.0 g, 2.187 mmol) and 60
`rhodium (II) diacetate (37 mg, 0.08 mmol) in benzene
`(50 mL) was heated to reflux and ethyl diazoacetate
`(750 mg, 690 µL, 6.56 mmol) in benzene (10 mL) was
`added over 10 min. The mixture was concentrated and
`purified by chromatography (silica gel, ethyl acetate- 65
`hexane, 1:1) to give 700 mg of product (32%) as a glas.s.
`The product was stirred with hexane with the addition
`of small amounts of ethyl acetate, ether and methylene
`
`wherein RI is
`
`

`
`7
`
`5,233,036
`
`R2 is hydrogen, alkyl of 1-6 carbon atoms, cycloalkyl of
`3-8 carbon atoms which is optionally unsaturated
`phenylalkyl of7-10 carbon atoms, or phenyl which is
`optionally mono-, di-, or tri-substituted with a substit(cid:173)
`uent selected from alkyl of 1-6 carbon atoms, alkoxy
`of 1-6 carbon atoms, hydroxy, cyano, halo, nitro,
`
`5
`
`8
`carbalkoxy of 2-7 carbon atoms, trifluoromethyl,
`amino, or a carboxylic acid;
`or a pharmaceutically acceptable salt thereof when R 2 is
`hydrogen.
`2. A compound of claim 1 where R2 is alkyl of 1-6
`carbon atoms.
`3. A compound of claim 1 which is 42-deoxy-42-(2-
`ethoxy-2-oxoethoxy)rapamycin.
`4. A compound of claim 1 which is 42-deoxy-42-(2-
`10 (1, 1-dimethylethoxy)-2-oxoethoxy ]-rapamycin.
`• • • • •
`
`15
`
`20
`
`25
`
`30
`
`35
`
`40
`
`45
`
`50
`
`55
`
`60
`
`65

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket